U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula AsI3
Molecular Weight 455.635
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARSENIC TRIIODIDE

SMILES

I[As](I)I

InChI

InChIKey=IKIBSPLDJGAHPX-UHFFFAOYSA-N
InChI=1S/AsI3/c2-1(3)4

HIDE SMILES / InChI

Molecular Formula AsI3
Molecular Weight 455.635
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Arsenic trioxide (ATO) is used to treat acute promyelocytic leukemia in people who have not been helped by other types of chemotherapy or whose condition has improved but then worsened following treatment with other types of chemotherapy. Arsenic trioxide acts through activation of Jun N-terminal kinase (JNK), activator protein-1, and inhibition of dual-specificity phosphatases. Although the exact mechanisms under which ATO exerts its therapeutic effect in acute promyelocytic leukemia cancer cells are not well elucidated. It was shown that apoptotic mechanisms involved the induction of phosphatidylserine externalization, caspase-3 activation, and nucleosomal DNA fragmentation. Adverse reactions described are leukocytosis, nausea, vomiting, diarrhea, and abdominal pain, fatigue, edema, hyperglycemia, dyspnea, cough, rash or itching, headaches, and dizziness.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TRISENOX

Sample Use Guides

In Vivo Use Guide
Induction Treatment Schedule: TRISENOX™ should be administered intravenously at a dose of 0.15 mg/kg daily until bone marrow remission. Total induction dose should not exceed 60 doses. Consolidation Treatment Schedule: Consolidation treatment should begin 3 to 6 weeks after completion of induction therapy. TRISENOX™ should be administered intravenously at a dose of 0.15 mg/kg daily for 25 doses over a period up to 5 weeks.
Route of Administration: Intravenous
Substance Class Chemical
Record UNII
3029988O2T
Record Status Validated (UNII)
Record Version